Money for Medication: A randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with a psychotic disorder and comorbid substance abuse.

Money for Medication: A randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with a psychotic disorder and comorbid substance abuse. - Money for Medication (M4M) in patients with a dual diagnosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34809

Enrollment

168

Registered

2010-05-21

Start date

2010-07-31

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Disorder in the perception of reality 2. Disorder with periods of hallucinations delusions or disorganization

Interventions

The proposed intervention is money for medication. Money for medication is based on Contingency Management (CM) principles. The essence of CM-based interventions is that a pre-set desirable behaviou

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 - 65 years 2. Psychotic disorder (including schizophrenia, schizoaffective disorder or other psychotic disorders) 3. Substance use disorder (alcohol and/or drugs) 4. An indication for antipsychotic depot medication 5. Outpatient treatment (either starting outpatient treatment or being in outpatient treatment for at least four months and having missed at least 50% (cf. Priebe, 2009) of prescribed depot medications). 6. Have given informed consent

Exclusion criteria

Exclusion criteria: 1. Not meeting all inclusion criteria 2. Inability to participate in this study due to cognitive impairments 3. Inability to understand the Dutch language sufficiently to participate in this study

Design outcomes

Primary

Measure	Time frame
The primary outcome measure of the current study is the number (percentage) of accepted depot injections. This number is defined as the Medication Possession Ratio (MPR) first reported by Sclar, Chin and Skaer (1991). The MPR is the number of accepted depots antipsychotic medication divided by the number of prescribed depots antipsychotic medication (the number of supplies needed for continuous use of antipsychotic medication).	—

Measure

Time frame

The primary outcome measure of the current study is the number (percentage) of accepted depot injections. This number is defined as the *Medication Possession Ratio* (MPR) first reported by Sclar, Chin and Skaer (1991). The MPR is the number of accepted depots antipsychotic medication divided by the number of prescribed depots antipsychotic medication (the number of supplies needed for continuous use of antipsychotic medication).

—

Secondary

Measure	Time frame
Our secondary outcome measures include the longest period of uninterrupted depot acceptance, the time expired before the depot is taken, the number of admissions in psychiatric hospitals, the effort initiated by the clinicians to provide the depot, patients symptomatology, social and psychological functioning, substance abuse, subjective quality of life and subjective wellbeing under neuroleptics. We will also assess cost-effectiveness of M4M from a societal perspective. Furthermore, we will explore how medication acceptance is related to impulsivity, patients attitudes towards medication and we will explore patients and clinicians attitudes towards M4M.	—

Measure

Time frame

Our secondary outcome measures include the longest period of uninterrupted depot acceptance, the time expired before the depot is taken, the number of admissions in psychiatric hospitals, the effort initiated by the clinicians to provide the depot, patients symptomatology, social and psychological functioning, substance abuse, subjective quality of life and subjective wellbeing under neuroleptics. We will also assess cost-effectiveness of M4M from a societal perspective. Furthermore, we will explore how medication acceptance is related to impulsivity, patients attitudes towards medication and we will explore patients and clinicians attitudes towards M4M.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)